Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1321 to 1335 of 2026 results for nice guidelines

  1. Mechanical clot retrieval for treating acute ischaemic stroke (HTG403)

    Evidence-based recommendations on mechanical clot retrieval for treating acute ischaemic stroke in adults. This involves using a device to remove the blood clot from the brain to restore normal blood flow.

  2. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)

    Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.

  3. Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils (TA1142)

    Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults.

  4. Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

    Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.

  5. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

  6. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

  7. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for stress urinary incontinence

    Surgery for stress urinary incontinence Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last...

  8. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

  9. Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)

    Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.

  10. Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

    Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.

  11. Urethrotech UCD for difficult or failed catheterisation (MIB116)

    NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .

  12. Devices for remote monitoring of Parkinson's disease (HTG657)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.

  13. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.

  14. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA1129)

    Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

  15. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis